Ekso Bionics Holding ((EKSO)) has held its Q2 earnings call. Read on for the main highlights of the call.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The recent earnings call for Ekso Bionics Holding presented a mixed sentiment. While the company faced significant declines in revenue, gross margin, and an increase in net loss, there were promising developments in the Personal Health segment, strategic partnerships, and AI initiatives. Management expressed optimism about recovering deferred sales and continued growth in Personal Health products.
Growth in Personal Health Product Revenues
Ekso Bionics reported a robust growth in its Personal Health product revenues, which surged by more than 50% year-over-year in the first half of 2025. This growth highlights the increasing demand and market acceptance of their Personal Health offerings, providing a positive outlook amidst other financial challenges.
Partnership with PRIA Healthcare
The company has strategically partnered with PRIA Healthcare, a leader in market access services, to better navigate the complexities of coding, coverage, and payment for its Ekso Indego Personal product. This partnership is expected to enhance the marketability and accessibility of Ekso’s products, potentially driving future revenue growth.
Introduction of eksoUniversity
Ekso Bionics launched eksoUniversity, a virtual platform aimed at providing continuing education courses to physical therapists. This initiative is designed to raise awareness and adoption of exoskeleton technology, potentially expanding the company’s influence and customer base in the rehabilitation sector.
AI Development through NVIDIA Connect Program
In a move to integrate advanced technologies, Ekso Bionics joined the NVIDIA Connect program. This collaboration aims to develop a proprietary foundation model for human motion and physical rehabilitation, enhancing their devices with AI capabilities and potentially revolutionizing the rehabilitation process.
Significant Revenue Decline
The company experienced a notable decline in revenue, with second quarter 2025 figures dropping to $2.1 million from $5 million in the same period of 2024. This decrease was primarily attributed to delays in multi-device Enterprise Health sales, posing a short-term challenge for the company.
Decrease in Gross Margin
Ekso Bionics reported a decrease in gross margin for Q2 2025, which fell to 40% from 53% in Q2 2024. The decline was due to fixed costs of goods and increased shipping expenses, impacting the company’s profitability.
Increased Net Loss
The net loss for Q2 2025 increased to $2.7 million, compared to a net loss of $2.4 million in the same period of 2024. This increase reflects the financial pressures faced by the company amidst declining revenues and gross margins.
Delays in Enterprise Health Sales
Short-term delays in completing significant multi-unit Enterprise Health device sales have impacted Ekso Bionics’ revenue performance. These delays are seen as temporary setbacks, with the company remaining optimistic about closing deferred sales in the near future.
Forward-Looking Guidance
Despite the current financial challenges, Ekso Bionics remains optimistic about the future. The company anticipates increased contributions from Personal Health products, supported by strategic partnerships and initiatives like eksoUniversity and AI integration through the NVIDIA Connect program. Management is hopeful about closing deferred sales and recovering from the temporary revenue setbacks.
In conclusion, Ekso Bionics’ recent earnings call highlighted a mixed financial performance, with significant challenges in revenue and profitability. However, the company’s strategic initiatives in Personal Health, partnerships, and AI development offer a promising outlook. Management’s optimism about overcoming short-term setbacks and achieving growth in key areas provides a hopeful perspective for investors and stakeholders.